INTRODUCTION
Medicine is divided into three branches: diagnosis, prognosis, and treatment. Treatment was the weakest of the three areas prior to the rise of modern medicine. Since then, diagnosis and treatment have become the predominant focus of clinicians, causing prognosis to wither.
1 "How long have I got doctor?" is a difficult question often faced by physicians. 2 Evidence suggests that there are negative consequences for those who are unaware of the progression of their disease and their current status. As a result, unsatisfactory management of advanced illness can arise, leading to unnecessary hospital admissions, higher proportion of hospital deaths, absence of or late referral to palliative care services, poor symptom control, less end-of-life planning, and reduced patient choice. 3 Patients who are terminally ill may often want to accomplish certain tasks before dying. However, predicting survival and disclosing the prognosis to patients with advanced disease is a difficult task for health care professionals. Often, patients are given an inaccurate prognosis. 2, 4 Clinicians are too optimistic or too pessimistic in their predictions. 5 In 1972, Parkes 6 found little relation between actual and predicted survival in terminally ill patients. Since then, there have been developments in the care of patients with terminal cancer. 7 Prediction of survival can help design and analyse clinical trials, allow for appropriate supportive services, guide clinical decisions, and assist in resource allocation. 4, 8 Previous studies have incorporated the use of prognostic tools when determining estimations. Such tools include performance status, patient symptomatology, quality-of-life measures, or biochemical parameters. 5 There is no single source of information to accurately provide a definitive prognosis. However, physicians may find information in the medical literature to assist in estimating survival time from patient attributes as well as their own clinical predictions. 2, 8 The objective of this study was to provide an update to a previous review in 2001 5 to examine the accuracy of clinicians' prediction of survival (CPS) in terminally ill patients as well as prognostic factors of survival.
METHODS
A search was conducted using the OvidSP platform on the following databases: MEDLINE (1 January 2000 -29 July 2012), Embase (1 January 2000 -22 July 2012), and Cochrane Database of Systematic Reviews (1 January 2005 -July 2012). The search terms "neoplasm or cancer or tumor", "terminally ill or terminal or palliative or metastases or advanced cancer or advanced neoplasm or advanced tumor" were coupled with "clinical prediction or survival prediction or prediction of survival or prognostic tool or physician predict", "prognostic indicator or prognostic factor or prognostic predictor and survival", or "forecast and survival".
Articles that met the following criteria were included: (1) patients aged 18 years and older, and (2) the study included a range of histological diagnoses to represent those commonly seen in hospices, palliative care Studies were excluded if they focused solely on utilising biochemical and molecular markers since routine blood tests are not commonly performed. This allowed for more representative systematic review for palliative care patients. A search was then conducted to identify additional articles that included relevant articles pulled from the OvidSP systematic search. Reference sections of reviews that were relevant to this study were also searched. Three of the authors independently identified articles of potential interest.
RESULTS
A total of 988 articles were identified from the search using the OvidSP platform. The titles and abstracts of the articles were manually checked to determine relevance. Articles that included only one primary cancer site, a sample population of one metastatic location, or only reported the use of biochemical markers were excluded. In the end, 85 articles were found to be relevant, some of which overlapped, examining both accuracy of clinicians' predictions and prognostic indicators of survival. As a result, 24 articles assessed the accuracy of clinicians' predictions and 71 examined prognostic factors and tools, with sample sizes ranging from 30 to 6066 patients. Accuracy of the clinicians' predictions was assessed by comparing the actual survival (AS) and estimated survival of the patients. The studies that examined the accuracy of survival predictions are summarised in Table 1 Abbreviation: PPI = Palliative Prognostic Index. * Patients were grouped by survival interval of <1 month, >1 month, <3 months, and >3 months; the optimistic and pessimistic errors were only reported at the 3-month interval. † Results for patients estimated to die within 1 month. ‡ Based on 100% error.
Clinicians' Prediction of Survival
Methods of obtaining CPS varied between the studies. Some clinicians estimated the survival in weeks or months. 6, 7, 9, [11] [12] [13] [14] 16, 18, 30 In addition to using a temporal approach to predict patient survival in days, in some studies, clinicians were asked to determine a probabilistic estimate of survival. Table 2 demonstrates the various studies and the time intervals in which estimates were given. 6, 7, 9, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] 30 
Methods of Determining Error
A variety of methods for determining error were employed between the studies. Several studies defined accuracy as the clinical prediction of survival within 33.3% of the actual survival. To calculate the error, the difference between the clinical and actual survival was divided by the actual survival and converted to a percentage. Values of <33.3% were pessimistic errors and values of >33.3% were optimistic errors. 9, 15, 17, 18 Another prominent calculation considered serious errors to be 100% errors in either overestimating or underestimating patient survival. An optimistic prediction would be a CPS that was double the observed survival, while a pessimistic prediction would be one where the patient lived twice as long as the predicted survival. 6, 12, 13, 30 Other methods were used by the remaining studies as summarised in Table 2 .
Accuracy of Clinician Prediction
Overall, studies reported a tendency to be too optimistic in their survival predictions. 6, 7, [9] [10] [11] [12] [13] [14] [15] [17] [18] [19] [20] [21] [22] 24, 25, [27] [28] [29] However, several studies noted a pessimistic trend in their estimates. 16, 23, 28 These studies reported varying survival durations at which the clinician's estimate was most accurate. Some articles reported significantly more accuracy in shorter survival durations. This phenomenon is known as the 'horizon effect'. 5 Higginson and Costantini 19 reported being closer to the actual survival of the patient than the maximum estimate with the average being 5 days shorter. When the minimum estimate was <2 weeks, accuracy increased to 70%. 19 Selby et al 22 concluded that predictions in the <24 hours and 1-7 days interval were more accurate if chosen (p < 0.0001). Fromme et al 25 noted that accuracy of survival prediction was inversely related to survival up to 6 months, declining from 85.6% for ≤3 days to 34.8%. Oxenham and Cornbleet 29 also observed more prediction accuracy in the last few days of a patients' life. On the contrary, Chow et al 10 noticed that when predicting for <12 weeks, the CPS was at least double the AS. However, the CPS estimates tended to be more accurate in the 27-to 52-week interval.
Differences among Clinicians
The CPS obtained from the studies was estimated by a variety of health care professionals. The studies exhibited discrepancy in whether different clinicians were more accurate in their predictions. Higginson and Costantini 19 reported a significant difference in accuracy between the four different palliative care team members (p < 0.001). Llobera et al 17 concluded that oncologists and oncology nurses showed similar prognostic ability, and primary care physicians who have less experience with terminally ill cancer patients were less accurate. Christakis and Lamont 15 commented that other nononcology medical specialists were 3 times more likely to underestimate survival than general physicians. These authors also noted that doctors in the upper quartile of practice experience were more likely to provide an accurate prediction. Maltoni et al 12 also reported a correlation between non-experienced and experienced clinicians. In this study, the correlation coefficient varied from 0.78 (p < 0.01) for most experienced physicians to 0.45 (p = 0.01) for novices in the home care team. Hui et al 18 noted that nurses were significantly more accurate in their prediction of survival at 24 hours (91% vs 71%; p < 0.001) and at 48 hours (86% vs 66%; p < 0.001). However, the authors also observed that physicians were significantly more likely than nurses to provide accurate prediction of survival for the 6-month time point (96% vs 88%; p = 0.006). In contrast, a few studies also indicated no significant differences in the accuracy of predictions across the varying disciplines. 6, 7, 11, 14, 26, 28 
Prognostic Indicators of Survival
A total of 71 articles investigating prognostic indicators of survival were extracted, and these are summarised in Tables 3 and 4. 11 -14,16,17,20,23,24,26,28,31-90 Not all identified prognostic factors were validated. Validation can be achieved through multiple methods, with the most common being: (1) performing a test analysis on a subsample of patients, followed by a subsequent validation analysis on the remaining patients; (2) repeating the analysis on an independent sample of patients; and (3) using the 'jack-knife' or 'bootstrap' procedures of performing the same analysis repeatedly on a series of subsets from the same data set to evaluate the stability of the coefficients and the predictive ability of the model. 5 Only 21 of the articles had been validated. 13, 16, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] Performance status was the most prominent prognostic factor determined to be significantly indicative of survival. Of the 45 studies that determined performance status to be predictive of survival, 11 utilised the Eastern Cooperative Oncology Group (ECOG) performance status, 32 observed that the patient-rated performance status from the patient-generated Subjective Global Assessment was similar to the PPS in predictability of survival and could be used as an alternative. Unlike the other studies, Chan et al 68 reported that magnitude of PPS change during the disease trajectory was an indicator of survival. Yates et al 54 noted the ability of KPS scores to accurately predict short survival, although high KPS scores did not correlate significantly with longer survival.
Assessment of Clinical Predictors of Survival
Although performance status has shown a correlation with survival, several studies have determined other prognostic factors used in combination with performance status to improve prediction. Reuben et al 56 concluded that KPS, dry mouth, dyspnoea, problems with eating, weight loss, and trouble swallowing comprised the 'common terminal pathway' and reduced survival time. Due to the limited population of hospice patients from the National Hospice Study database, Viganò et al 91 explored the common terminal pathway using a population-based cohort. The authors found that loss of function, malnutrition, and asthenia characterised the common terminal pathway.
In 1998, Pirovano et al 45 Liver cancer, systolic blood pressure, heart rate, haemoglobin, BUN, ECOG performance status, extremity muscle power, and male sex Rosenthal et al, 1993 61 
148
Poor ECOG performance status (3-4), admission at first referral to palliative care service, hyperbilirubinemia >19 µmol/l, hypotension (systolic blood pressure <90 mm Hg) Allard et al, 1995 62 
1081
Poor ECOG performance status = 4 prognostic factors from an earlier study 13 with the addition of biochemical parameters. The earlier study concluded that significant clinical predictors of survival were anorexia, dyspnoea, palliative steroid therapy, KPS score, and hospitalisation. 13 In the update, the group developed an assessment tool from an initial 36 variables using a backward selection procedure. As a result, the Palliative Prognostic Score (PaP Score) was constructed based on the following variables: clinical prediction of survival, KPS, anorexia, dyspnoea, total white blood cell count, and lymphocyte percentage. A numerical score was assigned to each variable based on the prognostic significance shown by each category in the multivariate analysis. The sum of the single scores gave the overall PaP Score for each patient, and was used to subdivide the study population into three groups with different probabilities of survival at 30 days -group A: probability of survival at 30 days of >70%, with patient score of ≤5.5; group B: probability of survival at 30 days of 30-70%, with patient score of 5.6-11.0; and group C: probability of survival at 30 days of <30%, with patient score of >11.0. The PaP Score based on clinical and biochemical variables was statistically significant in a multivariate analysis, and validated in the training set and in an independent case series. 92 Glare et al 23 reported that the PaP Score was able to accurately identify three prognostic groups within advanced cancer patients under the care of an 87 
198
Lack of appetite, drowsiness, dyspnoea, and fatigue Ventafridda et al, 1990 88 
120
Appearance of unendurable symptoms and aggravation of previous controllable symptoms (dyspnoea, pain, delirium, vomiting) Zeng et al, 2011 89 
808
Deterioration of global Edmonton Symptom Assessment System symptoms (pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, dyspnoea) Tsamandouraki et al, 1992 90 
202
Home care less effective compared with hospital care Caraceni et al 52 evaluated the impact of delirium on the survival of advanced cancer patients who were also assessed by using the PaP score. Delirium was found to significantly worsen the life expectancy associated with the PaP Score. Patients with delirium had a different survival curve when compared with nondelirious patients (p < 0.0001). This result suggested that assessing cognitive status and utilising the PaP Score could increase accuracy in >70% of patients when predicting 30-day survival. 52 Scarpi et al 41 also reported delirium to be statistically significant (p < 0.001) and therefore revised the PaP Score to incorporate delirium (D-PaP Score). This prognostic tool was retrospectively tested on the sample population from Caraceni et al 52 and determined to have a better overall performance than the PaP Score. 41 Morita et al 42 developed and validated a simple indicator for survival of <3 weeks or <6 weeks based on the presence of clinical symptoms. Risk factors were identified by multiple logistic regressions with a reported sensitivity and specificity of >70%. Since scoring methods were suggested to be more effective than prediction based on the presence of certain clinical symptoms, this same group went on to develop and subsequently validate a scoring system using the same patient population. 73 The Palliative Prognostic Index (PPI) evaluates performance status, oral intake, oedema, dyspnoea at rest, and delirium. In the training set, patients were classified into three groups -group A: PPI ≤2.0); group B: 2.0< PPI ≤4.0; and group C: PPI >4.0). When a PPI of >6.0 was adopted as a cut-off point, 3-week survival was predicted with a sensitivity of 80% and specificity of 85%. When a PPI of >4.0 was used as a cut-off, 6-week survival was predicted with a sensitivity of 80% and a specificity of 77%. The PPI was able to predict whether patients lived longer than 3 or 6 weeks. 73 In a later study, this group of authors compared the PPI with physician-predicted survivals. 16 The PPI was able to improve physicians' CPS, decreasing serious error from 27% to 16% (p = 0.028). Stone et al 39 validated the PPI with patients referred to a hospital-based consultancy palliative care service, a hospice home care service, and a hospice inpatient unit, and who were also receiving palliative chemotherapy or radiotherapy. Alshemmari et al 69 reported that the PPI may be helpful for oncologists in predicting survival and in-hospital mortality of patients with advanced cancer in the acute care setting.
Durand et al
44 constructed a different model consisting of urea >12 mmol/l, KPS <30%, leukocytes >15 g/l, transthyretin <0.05 g/l, and male sex to predict 2-week survival. A Cochin Risk Index Score of <7 identified high-risk patients resulting in a positive predictive value of 78% in the validation set.
Sloan et al 46 produced a simple stratification factor for phase III oncology clinical trials involving patients with advanced malignant disease known as the Good/ Bad/Uncertain (GBU) index. This index is based on CPS, performance status, patient-reported KPS score, and patient-rated appetite. Patients were classified as having a relatively good prognosis if three or more items showed a positive indication, a bad prognosis if three or more were negative, and an uncertain prognosis otherwise. The results of this study showed that the GBU index was able to improve the prognostic power of a Cox model quartile index and performance status alone, increasing the accuracy of survival classification estimates by 5 to 10%. For patients with performance status of 0 or 1, significant survival patterns existed b e t w e e n G B U g r o u p s ( p = 0 . 0 0 2 a n d 0 . 0001, respectively). 58 constructed an objective prognostic score that also incorporated performance status. Based on multivariate analysis, reduced oral intake, resting dyspnoea, low performance status, leukocytosis, elevated bilirubin, elevated creatinine, and elevated lactate dehydrogenase (LDH) were associated with poor prognosis. The objective prognostic score range is 0.0 to 7.0. For a cut-off score of 3.0, the 3-week prediction sensitivity is 74.7%, specificity is 76.5%, and overall accuracy is 75.5%. The instrument was able to demonstrate accurate prediction of 3-week survival in the training set, although it was not validated in an independent population. Chuang et al 35 developed a prognostic scale based on multivariate analysis that reported liver and lung metastases, ECOG performance status, weight loss, oedema, cognitive impairment, tiredness, and ascites to be independently associated with shorter survival. The scale ranged from 0.0 to 8.5. For scores of <3.5, 2-week survival was predicted with 0.72 and 0.61 accuracy for the training and testing sets, respectively, and for scores of <6.0, 1-week survival was predicted with 0.72 and 0.66 accuracy, respectively.
Suh et al
Chow et al 37 constructed a three-variable model for patients with metastatic cancer attending a palliative radiotherapy clinic using the readily available parameters of primary cancer site, site of metastases, and KPS. Each factor was assigned a value proportional to its prognostic weight and weighted scores for each patient were summed to obtain a survival prediction score. Patients were also grouped according to the number of risk factors (NRF): non-breast cancer, metastases other than bone, and KPS ≤60. The model was subsequently validated in temporal and external data sets, and the three-variable NRF model was preferred because of its relative simplicity. The same model was again validated using Radiation Therapy and Oncology Group (RTOG) 9714 data comprising patients treated at multiple institutions. 43 The NRF method was able to distinguish intermediate-risk patients that the survival prediction score method classified into a lowrisk group, yielding a statistically significant difference in survival estimates of the two groups (p < 0.0001). 43 Chow et al 40 also constructed a predictive model for patients referred to the Rapid Response Radiotherapy Program using recursive partitioning. Sixteen factors characterising patients with metastases at first referral were analysed. The model was able to separate patients into three groups with different survival durations, as follows: KPS >60, KPS <60 with bone metastases only, and KPS <60 with other metastases. The model was then validated temporally and externally, but only performed moderately well. There was no advantage to this model compared with the previous survival prediction score and NRF prognostic models.
Chiang et al 47 proposed a computer-assisted estimated probability formula for predicting death within 7 days of hospice admission in terminal cancer patients. This formula incorporated demographic, clinical, and laboratory data. The formula evaluated ECOG performance status, grade 3 oedema, muscle power, heart rate, respiratory rate, intervention tube, sex, haemoglobin, blood urea nitrogen, and serum glutamic pyruvate transaminase. This model exhibited an 82.3% accuracy when comparing using receiver operating characteristic curves.
Feliu et al
32 developed a prognostic nomogram for terminal cancer patients based on five clinical and laboratory variables to estimate probability of survival at 15, 30, and 60 days. The instrument was validated and calibrated with an external cohort. ECOG performance status, LDH, albumin levels, lymphocyte levels, and time from initial diagnosis to diagnosis of terminal disease were included in the multivariable Cox proportional hazard as prognostic factors of survival. These factors formed the nomogram and showed high predictive performance with a bootstrapped corrected concordance of 0.70 and an external independent validation of 68% accuracy.
Zhou et al
36 developed a simple Chinese Prognostic Scale (ChPS) for predicting survival in 1019 advanced cancer patients divided into two sets using stratified random sampling to obtain a 'training set' for developing the scale and a 'testing set' for validation. A total of 10 prognostic factors were determined: weight loss, nausea, dysphagia, dyspnoea, oedema, cachexia, dehydration, sex, KPS, and quality of life. The ChPS score was calculated by summing the partial scores of the prognostic factors from 0 (no altered variables) to 124 (maximal altered variables). The score cut-off point of 3 months' survival was 28. Patients with scores of >28 usually lived for <3 months. The training set had an accuracy of 69.4%, while the validation set had 65.4% accuracy.
Three models were constructed without the use of performance status to aid in estimated patient survival. 31, 33, 75 Ohde et al 31 developed a prognostic p r e d i c t i o n m o d e l f o r 2 -w e e k s u r v i v a l a m o n g patients with terminal cancer in a palliative care unit. A prognostic model with a total of 8 points was constructed, as follows: 2 points each for anorexia, dyspnoea, and oedema; 1 point each for blood urea nitrogen >25 mg/dl and platelets <260,000/mm 3 . Bootstrapped validation beta coefficients were similar to the original cohort beta coefficients. When total scores were 0-1 point, 2-3 points, 4-5 points, or >6 points, 2-week mortality rates were 7.7%, 19.4%, 59.3%, and 100% respectively. This model has yet to be externally validated.
Hyodo et al 33 studied 32 clinical predictors to develop a new tool, the Japan Palliative Oncology StudyPrognostic Index, using the Cox proportional hazard model. Five significant predictors were included: CPS, consciousness, pleural effusion, white blood cell count, and lymphocyte percentage were used to divide the patients into three risk groups: low (group A), intermediate (group B), and high (group C). The probability for survival of >30 days for groups A, B, and C were 78%, 61%, and 16%, respectively. The validation set yielded consistent results (81%, 48%, and 11% for groups A, B, and C, respectively).
Yun et al 75 developed the Terminal Cancer Prognostic (TCP) score, a prognostic index for terminal cancer patients. After adjusting for primary tumour site, three predictors were negative predictors of survival: anorexia, severe diarrhoea, and mild confusion. The tool ranged from a score of 0 (none of the variables) to 7 (all variables) with 2 points for anorexia, 3 for diarrhoea, and 2 for confusion. The TCP score was proved to have a strong association with survival.
Rosenthal et al 61 also reported certain clinical and laboratory data to be significantly associated with shorter survival. This group reported poor ECOG performance status (3) (4) , admission at first referral to palliative care service, hyperbilirubinemia (>19 μmol/l), and hypotension (systolic blood pressure, <90 mm Hg) as indicators. Bachelot et al 59 only found laboratory data in combination with performance status to be significant. These authors noted LDH of >600 IU and ECOG performance status 2 or 3 to be predictive of survival.
In combination with performance, few studies found survival to be related to the type of primary cancer. 26, 49, 60, 65, 71, 76, 78 Gripp et al 26 determined colorectal and breast cancer had a favourable prognosis, whereas brain metastasis was associated with a poor prognosis. Kao et al 60 reported shorter survival among patients diagnosed with liver cancer. Hardy et al 78 determined that a lung primary was associated with survival prediction. Lau et al 71 reported initial PPS score, age, diagnosis, cancer type, and site to be prognostic factors associated with shorter survival. These researchers went on to find initial PPS score, age, diagnosis, sex, and location that the PPS was recorded to be significant predictors of survival time. 72 Two other studies also found sex to be indicative of survival. 66, 74 Weng et al 66 found PPS, age, and sex to be predictive of shorter survival. Younis et al 74 reported survival to be correlated with only PPS and sex. Other studies have found the number of metastatic sites rather than the type of primary site to be prognostic of survival. 51, 57 Application of physical indicators has been suggested, but different assessment tools were used to assess these factors. Many studies also showed a relationship between survival and other quality-of-life components or symptoms, most of which reported performance status as affecting duration of survival. 17, 28, 50, 53, 63, 64, 81 Other studies have concluded certain quality-oflife symptoms to be significant, but not performance status. 11, 34, 38, 80, [82] [83] [84] 88, 89 Ventafridda et al 88 noted appearance of unendurable symptoms and aggravation of previous controllable symptoms in 97% of patients within 1 week of death and >50% of patients in the last 24 hours. As the 'unendurable' and 'difficult to control' symptoms were not specifically or clearly defined, this study had limited clinical applicability. 5 Similarly, Zeng et al 89 reported a significant deterioration of global Edmonton Symptom Assessment System (ESAS) symptoms within the last 4 weeks prior to death compared with the scores in previous months. At 1 week prior to death, the worst ESAS symptoms were fatigue, appetite, and well-being. Tsamandouraki et al 90 noted that although the quality of life of patients cared for at home was superior to that of patients in hospital, home care was less effective when survival was the only outcome criterion.
The presence of dyspnoea was noted in a few studies as an indication of patient survival. [85] [86] [87] Cuervo Pinna et al 85 found that patients with incident dyspnoea had higher average survival duration than those with prevalent dyspnoea. Vitetta et al 86 also described dyspnoea as having a negative effect on survival, along with pain, immobility, and adjusted Charlson comorbidity score. Cheung et al 87 noticed lack of appetite, drowsiness, dyspnoea, and fatigue to be independent prognostic factors.
DISCUSSION
CPS was determined to be correlated with survival in a few of the studies reviewed, 13, 17, 23, 33, 41, 45, 46, 48, 52, 77 however, predictions tended to be too optimistic. 6, 7, [9] [10] [11] [12] [13] [14] [15] [17] [18] [19] [20] [21] [22] 24, 25, [27] [28] [29] In a study comparing physician behaviour in disclosing prognostic expectations, Lamont and Christakis 93 found that physicians provided frank survival estimates only 37% of the time and knowingly inaccurate estimates 40.3% of the time, tending to be more optimistic than the formulated predictions. Disinterested doctors with little time to get to know a patient may be able to provide a more accurate prognosis. 26 Experience with terminal cancer may help to improve the ability to predict survival. Llobera et al 17 found oncology nurses and oncologists to have similar prognostic ability compared with primary care physicians who are less experienced in caring for terminally ill patients. Nurses, who had more experience at a patient's bedside than physicians and therefore were better able to pick up imminent signs of death, showed a higher accuracy when predicting the last 24 hours of life. 18 Although physicians incorrectly predict survival, the fact that predictions are correlated with survival indicates that they are able to sense when things are going wrong. 94 The results suggest that clinicians are able to separate patients into classes, although they may be poorly calibrated due to the inability to assign meaningful probabilities to outcomes. 94 Inaccurate predictions have been reported to have negative effects. 5 Optimistic life expectancy can cause patients to be denied eligibility for services to improve their quality of dying, while erroneously pessimistic results may negatively impact the financial status of hospice programmes by leading to provision of uncompensated care for patients who live longer than 6 months. 95 Palliative care requires a patient-oriented active approach. An important step in preventing adverse consequences of an incorrect prognosis is to be aware of possible incomplete diagnostics. 96 If doctors are able to better anticipate death, medical treatments and use of palliative care can be optimised, allowing patients to avoid unnecessary treatments near the end of life. 94 The prevalence of similar symptoms among patients with varying primary and metastatic sites supports the existence of a common final clinical pathway or 'terminal common pathway' in patients with advanced cancer. 56 To better assess survival duration, many assessment tools have been developed and validated. The instruments have a range of prognostic factors, containing a varying combination of demographic data, symptoms, and laboratory data. The differences may be due to the varying purposes and outcomes of the study. For example, Chow et al 37 used readily available parameters to construct a three-variable model. Also, the requirements for inclusion in sample populations were different for each study, potentially influencing the outcome as noted by Viganò et al. 91 Depression as a prognostic factor resulted in contradicting opinions. Teunissen et al 38 found the absence of depression to be indicative of survival, whereas Lloyd-Williams et al 83 reported the presence of depression to be prognostic. Teunissen et al 38 suggested
that the depression and cancer progression relationship resulted from the use of questionnaires rather than from psychiatric (Diagnostic and Statistical Manual of Mental Disorders) criteria. The associations may be reflective of symptoms mimicking depression, but are in fact markers of tumour burden or cancer progression. 38 Treatment for patients with terminal cancer shifts from curative to palliative, focusing on relieving symptoms and managing complications. 97 Many studies have determined the prognostic value of biochemical parameters in palliative care. However, since the goal of care is to relieve pain and maintain quality of life, routine blood tests are avoided. 5 Assessment tools should be convenient in order to reduce the burden on terminally ill cancer patients, therefore, instruments that rely on demographic information or clinical symptoms should be emphasised.
The absence of optimistic errors cannot be avoided due to the nature of terminal cancer. 16 The clinical value of individual prognostication is limited, even with the use of an assessment tool as shown by Morita et al. 16 Clinicians should inform patients and their friends and family of the uncertainty in survival prediction.
Limitations
Due to the heterogeneity of the patient populations used in the studies, it is difficult to draw a conclusion on which clinical symptoms are predictors for survival. Many of the studies that determine prognosis factors for survival did not subsequently undergo validation. Future studies should compare the different assessment tools using the same patient population in order to better assess the validity and outcome of each for terminally ill cancer patients.
